084990.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 14:30):

Stats
今日成交量	47 660.00
平均成交量	455 522
市值	215.19B
EPS	KRW0 ( 2024-02-13 )
下一个收益日期	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW5.39 (0.12%)

音量相关性

長: -0.26 (neutral)

短: 0.00 (neutral)

Signal:(43.471) Neutral

Helixmith Co., Ltd 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Helixmith Co., Ltd 相关性 - 货币/商品

-0.29
( neutral )

-0.31
( neutral )

0.36
( neutral )

0.58
( weak )

0.10
( neutral )

0.66
( moderate )

Helixmith Co., Ltd 财务报表

Annual	2023
营收:	KRW4.20B
毛利润:	KRW-8.57B (-204.02 %)
EPS:	KRW-1 543.76

FY	2023
营收:	KRW4.20B
毛利润:	KRW-8.57B (-204.02 %)
EPS:	KRW-1 543.76

FY	2022
营收:	KRW2.80B
毛利润:	KRW-10.03B (-358.20 %)
EPS:	KRW-1 153.75

Financial Reports:

No articles found.

Helixmith Co., Ltd

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501, a re-engineered form of interleukin 11 targeting chemotherapy-induced thrombocytopenia. Its clinical trials biologics comprise VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. The company was formerly known as ViroMed Co., Ltd. and changed its name to Helixmith Co., Ltd in April 2019. Helixmith Co., Ltd was incorporated in 1996 and is headquartered in Seoul, South Korea.